The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. (Q54535188)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. |
scientific article |
Statements
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. (English)
1 reference
Toshio Shimizu
1 reference
Anthony W Tolcher
1 reference
Kyriakos P Papadopoulos
1 reference
Muralidhar Beeram
1 reference
Drew W Rasco
1 reference
Lon S Smith
1 reference
Shelly Gunn
1 reference
Leslie Smetzer
1 reference
Theresa A Mays
1 reference
Brianne Kaiser
1 reference
Michael J Wick
1 reference
Cathy Alvarez
1 reference
Aracely Cavazos
1 reference
Gina L Mangold
1 reference
Amita Patnaik
1 reference
19 January 2012
1 reference
18
1 reference
8
1 reference
2316-2325
1 reference
Identifiers
1 reference